SCHEMBL7095750

SCHEMBL7095750

CC1OC(=O)N(C(=O)O)C1c1ccc(F)c(F)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA1A P35348 5/20 0.52
ADRA1B P35368 4/20 0.52
ADRA1D P25100 3/20 0.52
HRH1 P35367 1/20 0.52
HTR7 P34969 1/20 0.34
HCAR3 P49019 1/20 0.34
HCAR2 Q8TDS4 1/20 0.34
IDO1 P14902 2/20 0.33
TDO2 P48775 2/20 0.33
TSHR P16473 1/20 0.32
EDNRB P24530 1/20 0.32
ADAMTS5 Q9UNA0 2/20 0.31
GRM2 Q14416 1/20 0.31
ATM Q13315 1/20 0.31
CES2 O00748 1/20 0.31
CES1 P23141 1/20 0.31
AKR1B1 P15121 1/20 0.31
ABCB1 P08183 1/20 0.31
ABCG2 Q9UNQ0 1/20 0.31
KDM1A O60341 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6082094 1.00 ADRA1A (0.52) ADRA1AADRA1BADRA1DHRH1HTR7
SCHEMBL6959819 1.00 ADRA1A (0.52) ADRA1AADRA1BADRA1DHRH1HTR7
SCHEMBL14587409 0.89 ADRA1A (0.52) ADRA1AADRA1BADRA1DHRH1HTR7
SCHEMBL7083169 0.82 ADRA1A (0.40) ADRA1AADRA1BADRA1DHRH1HTR7
SCHEMBL7075810 0.82 ADRA1A (0.40) ADRA1AADRA1BADRA1DHRH1HTR7
SCHEMBL7083166 0.82 ADRA1A (0.40) ADRA1AADRA1BADRA1DHRH1HTR7
SCHEMBL6961998 0.80 ADRA1A (0.41) ADRA1AADRA1BADRA1DHRH1HTR7
SCHEMBL6961064 0.80 ADRA1A (0.41) ADRA1AADRA1BADRA1DHRH1HTR7
SCHEMBL7972617 0.80 ADRA1A (0.39) ADRA1AADRA1BADRA1DHRH1HTR7
SCHEMBL8172549 0.78 EPHX1 (0.43) ADRA1AADRA1BADRA1DHRH1HTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1023068-A4 ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS MERCK & CO INC (US) 2001-05-16 EP claimed
EP-1023068-A1 ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 2000-08-02 EP claimed
WO-1998057638-A1 ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1998-12-23 WO claimed
US-20030082623-A1 DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof H. LUNDBECK A/S (DK) 2003-05-01 US disclosed
US-6376503-B1 TREATMENT OF BENIGN PROSTATIC HYPERPLASIA MERCK & CO., INC 2002-04-23 US disclosed
EP-1023068-A4 ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS MERCK & CO INC (US) 2001-05-16 EP disclosed
EP-1023068-A1 ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 2000-08-02 EP disclosed
WO-1998057638-A1 ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1998-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030082623-A1 DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof MCHR1, MCHR2, MC1R ADRA1A 224/4885ADRA1B 306/4885ADRA1D 247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.